An Open-Label Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma.
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2015
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Cephalon; Teva Pharmaceutical Industries
- 14 Feb 2012 Actual patient number (40) added as reported by ClinicalTrials.gov.
- 14 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.